
|Videos|November 19, 2016
Phase III EF-14 Trial Shows Tumor Treating Fields Improve OS in Brain Cancer
Author(s)Roger Stupp, MD
Results from the EF-14 trial which compared standard of care for glioblastoma plus or minus the tumor treating fields.
Advertisement
Roger Stupp, MD, professor of oncology, University of Zurich, discusses the EF-14 trial which compared standard of care for glioblastoma plus or minus tumor treating fields with Optune. Median overall survival was 20.8 months for temozolomide plus Optune versus 16.0 months for temozolomide-alone (HR, 0.65; 95% CI, 0.54-0.79;P
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5








































